DelveInsight’s “Immune Thrombocytopenia (ITP) – Market Insights, Epidemiology, and Market Forecast–2032” report delivers an in-depth understanding of ITP historical and forecasted epidemiology as well as the Immune Thrombocytopenia market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Key Highlights Immune Thrombocytopenia Market
Key Companies working in the Thrombocytopenic Purpura market are Immune Thrombocytopenia market are UCB Biopharm, Sanofi, Principia Biopharma, Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, and many others.
Key Therapies in Immune Thrombocytopenia are Rilzabrutinib, Efgartigimo, and many others.
The market size for the Immune Thrombocytopenia market is USD 3,100 million in 2021.
.The CAGR for the Immune Thrombocytopenia market is XX%
Immune Thrombocytopenia Overview
Immune Thrombocytopenia, previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. The normal platelet level in adults is between 150,000/mm3 and 450,000/mm3. Platelet counts below 50,000/mm3 increase the risk of dangerous bleeding from trauma; counts below 20,000/mm3 increase the risk of spontaneous bleeding. Immune Thrombocytopenia is caused by various etiologies characterized by increased platelet destruction and impaired production, resulting in a decreased platelet count. Primary ITP is idiopathic, whereas secondary Immune Thrombocytopenia is linked to an underlying condition. When PNH is associated with AA, most patients express only a small PNH clone (<10%). Physicians could find clinical and/or biological evidence of hemolysis associated with two or three cytopenias (Hb
Immune Thrombocytopenia Epidemiology
In 2021, the total cases of ITP were ~184,000 cases in the 7MM. These cases are expected to increase by 2032.
The United States, in 2021, accounted for the highest number of cases of ITP that were 65,500 cases. These cases are expected to increase by the year 2032.
In 2021, Japan accounted for ~27,200 cases of ITP, which was approximately 15% of the total ITP cases in 7MM.
In the UK, out of the total diagnosed prevalent cases, there were ~570 cases and ~21,400 cases of Immune Thrombocytopenia in children and adults, respectively in 2021. These cases are expected to increase by 2032.
Out of the total diagnosed prevalent cases, Japan accounted for ~740 cases in children and ~21,200 cases of ITP in adults in 2021.
Click here to learn more about the Immune Thrombocytopenia Market Landscape
The Report Covers the Immune Thrombocytopenia Epidemiology Segmented by:
Immune Thrombocytopenia diagnosed prevalent population
Immune Thrombocytopenia gender-specific diagnosed prevalent population
Immune Thrombocytopenia Market Outlook
Immune Thrombocytopenia is characterized by low platelet counts and an increased tendency to bleed. Although ITP generally presents as a subtle-onset, chronic disorder in adults, clinical manifestations can range from petechia, purpura, and bruising to overt bleeding, such as gastrointestinal or intracranial hemorrhaging. When treatment is deemed necessary, typical first-line therapies include corticosteroids, intravenous immunoglobulin (IVIg), and Rho (D) immune globulin, also referred to as anti-D immune globulin (IV anti-D). Relapse or failure to respond to these drugs may necessitate second-line treatment, including various medical options and splenectomy.
In Immune Thrombocytopenia, the first-line treatment option is generally corticosteroids. The recommended prednisone dose is 1 mg/kg/day orally for up to 21–28 days depending upon the response, followed by slow tapering. More prominent platelet responses have been reported with repeated pulses of high-dose dexamethasone 40 mg daily for 4 days.
Also, intravenous immunoglobulin or intravenous anti-D (Rho [D] immune globulin) is used as an initial treatment with or without steroids. Most adult patients will relapse after initial treatment (or are refractory to first-line therapy) and require second-line therapy. Intravenous immunoglobulin (IVIG) therapy is administered to patients requiring rapid or urgent elevation of platelet count (e.g., intraoperative or life-threatening bleeding). IVIg increases the platelet count in 70–80% of treated patients, often within days. Several IVIg regimens have been employed, but many hematologists prefer the convenience of a 1 g/kg/day infusion for 1–2 days. Anti-D immunoglobulin (anti-D) binds to Rh (D) antigen on erythrocytes, thereby leading to the clearance of antibody-coated cells and inhibiting the clearance of opsonized platelets by the reticuloendothelial system. Therefore, anti-D is effective only in RhD-positive individuals, and anti-D has been reported effective in approximately 50–70% of patients treated with this agent.
And many others
Immune Thrombocytopenia Therapies Covered and Analyzed in the Report
And many others.
Learn more about the Key Companies and Emerging Therapies in the Immune Thrombocytopenia Market
Table of Contents
Immune Thrombocytopenia Introduction
Executive Summary of Immune Thrombocytopenia
Disease Background and Overview
Epidemiology and patient population
Immune Thrombocytopenia Emerging Therapies
Immune Thrombocytopenia Market Outlook
Market Access and Reimbursement of Therapies
Learn about the detailed offerings of the report @ Immune Thrombocytopenia Market Outlook
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States